Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MINOXIDIL EXTRA STRENGTH (FOR MEN) vs Hydralazine
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arterioles. It increases blood flow to hair follicles and prolongs the anagen (growth) phase of hair follicles.
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased peripheral vascular resistance and blood pressure. Its exact mechanism is unclear but may involve interference with calcium movement and increased c GMP levels.
Treatment of androgenetic alopecia (male pattern baldness) in men,Off-label: female pattern hair loss, alopecia areata, chemotherapy-induced alopecia, beard enhancement
Hypertension (adjunctive therapy),Off-label: Chronic heart failure (in combination with isosorbide dinitrate, especially in African American patients)
Topical: 1 m L of 5% solution (50 mg) applied to the scalp twice daily. Maximum daily dose: 2 m L (100 mg).
10-50 mg orally every 6 hours, titrate to maximum 300 mg/day; 10-20 mg intramuscularly or intravenously every 4-6 hours as needed.
Terminal elimination half-life is approximately 4.2 hours in patients with normal renal function. However, the pharmacodynamic half-life (duration of antihypertensive effect) is about 24 hours, allowing once-daily dosing.
The terminal elimination half-life of hydralazine is approximately 2-4 hours in patients with normal renal function. However, the duration of antihypertensive effect may be longer (6-12 hours) due to tissue binding and slow release from vascular smooth muscle. In renal impairment, half-life may extend to 7-16 hours, necessitating dose adjustment.
Primarily metabolized by glucuronidation via UGT1A1 and UGT1A3 enzymes; minor metabolites include minoxidil sulfate, which is active.
Primarily hepatic via acetylation (N-acetyltransferase 2, NAT2). Metabolites include hydralazine pyruvic acid hydrazone and acetylhydralazine.
Primarily renal (approximately 95% as parent drug and metabolites). Biliary/fecal excretion is minimal (less than 5%).
Hydralazine is primarily metabolized in the liver via N-acetylation and hydroxylation. Approximately 80-90% of the drug is eliminated in urine as metabolites, with less than 10% excreted unchanged. A small fraction appears in feces via biliary excretion.
About 20% bound to plasma proteins (primarily albumin).
85-90% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 3-4 L/kg, indicating extensive distribution into tissues.
1.5-2.0 L/kg. This high Vd indicates extensive tissue binding and accumulation in vascular smooth muscle.
Oral: Approximately 90% absorbed, but bioavailability is around 50% due to first-pass metabolism. Topical: Systemic absorption is minimal (approximately 1.4-5% of applied dose).
Oral: 10-30% due to extensive first-pass metabolism. Bioavailability is lower in fast acetylators. Bioavailability is 100% for intravenous administration.
No dose adjustment required for topical minoxidil. For oral minoxidil (off-label for hypertension): GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, reduce dose by 75%.
GFR 10-50 m L/min: administer every 8-12 hours; GFR <10 m L/min: administer every 12-24 hours.
No specific guidelines for topical minoxidil. For oral minoxidil: Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%.
Child-Pugh A: caution, consider starting at 25% of normal dose; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not recommended for use in children under 18 years for androgenetic alopecia. Safety and efficacy not established.
0.75-1 mg/kg/day orally divided every 6-12 hours, maximum 7.5 mg/kg/day; intravenous: 0.1-0.2 mg/kg/dose every 4-6 hours as needed.
No specific dose adjustment required for topical use. Monitor for orthostatic hypotension or fluid retention with oral use. Start at lower end of dosing range if using oral minoxidil.
Start at 10 mg orally twice daily, increase slowly; monitor for hypotension and reflex tachycardia; maximal dose 200 mg/day.
None
Systemic lupus erythematosus-like syndrome (drug-induced lupus) with long-term use at high doses.
Cardiovascular effects: tachycardia, fluid retention, pericardial effusion (rarely) – risk increases with systemic absorption; avoid use in patients with pheochromocytoma or hypertensive crisis,Hypotension: can occur if applied to broken skin or excessive application,Dermatologic: contact dermatitis, scalp irritation, unwanted facial hair growth (hypertrichosis),Cardiac: avoid in patients with known coronary artery disease or arrhythmias
May cause drug-induced lupus erythematosus; discontinue if symptoms develop.,Peripheral neuritis (pyridoxine deficiency) with long-term use.,May precipitate angina or myocardial infarction in patients with coronary artery disease.,Tachycardia and palpitations may occur; use with beta-blockers if needed.,Blood dyscrasias (rare).
Hypersensitivity to minoxidil or any component of the formulation,Concurrent use with other topical hair growth products
Hypersensitivity to hydralazine,Coronary artery disease (angina pectoris, myocardial infarction),Mitral valve rheumatic heart disease,Aortic aneurysm (relative)
No significant food interactions. Avoid excessive alcohol intake as it may worsen orthostatic hypotension if systemic absorption occurs.
Take with food or milk to reduce stomach upset and slow absorption. Avoid high-tyramine foods (e.g., aged cheese, cured meats, fermented products) if taking a combination product containing hydralazine and hydrochlorothiazide–though hydralazine alone has no known significant food interactions. Limiting salt intake enhances antihypertensive effect.
Minoxidil is pregnancy category C. First trimester: Animal studies show fetal abnormalities (skeletal, cardiovascular) at high doses; no adequate human studies. Second/third trimester: Possible fetal hypotension, hypertrichosis, and perinatal complications. Avoid use in pregnant women unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: No well-controlled studies; animal studies show no evidence of teratogenicity but embryotoxicity at high doses. Second/Third trimesters: Associated with maternal hypotension potentially reducing placental perfusion; no fetal malformations reported, but neonatal thrombocytopenia, lupus-like syndrome, and arrhythmias reported with chronic use near term.
Minoxidil is excreted in human milk. M/P ratio not reported. Potential for adverse effects in nursing infant (e.g., hypotension, fluid retention). Use caution; decide based on importance of drug to mother.
Excreted into breast milk in small amounts (M/P ratio estimated 1.0-1.4). No reported adverse effects in infants. American Academy of Pediatrics considers compatible with breastfeeding. Monitor infant for hypotensive effects or drug accumulation, especially in neonates or preterm infants.
No specific dose adjustment guidelines. Due to increased plasma volume and renal clearance during pregnancy, effectiveness may be reduced; monitor response and adjust dose as needed, but avoid excessive hypotension. Use lowest effective dose.
Increased volume of distribution and plasma clearance may require dose adjustments. Initial oral: 10 mg 4 times daily, titrate up to 300 mg/day. In severe hypertension, IV bolus (5-10 mg) may be used with caution. Monitor for reflex tachycardia and hypotension; dose titration based on maternal response.
Minoxidil extra strength (5%) is a topical vasodilator used for androgenetic alopecia. Onset of hair regrowth typically requires 4-6 months of twice-daily application. Initial shedding of telogen hairs may occur in the first 2-6 weeks due to synchronization of hair cycle. Use in patients with cardiovascular disease or those on antihypertensives may theoretically cause systemic effects but is rare at topical doses. Avoid concomitant use with other topical agents that may irritate scalp. Discontinue if no response after 12 months.
Hydralazine is a direct-acting vasodilator; first dose may cause profound hypotension—administer with food to减缓 absorption. Monitor for drug-induced lupus (especially in slow acetylators); baseline ANA recommended. Tachyphylaxis occurs; combine with beta-blocker and diuretic to counteract reflex tachycardia and fluid retention. Adjust dose in renal impairment (creatinine clearance < 10 m L/min).
Apply 1 m L to dry scalp twice daily, spreading evenly over affected areas.,Wash hands thoroughly after application to avoid unwanted hair growth.,Initial hair shedding is normal and indicates drug is working; do not stop.,Visible results may take 4-6 months; treatment is lifelong to maintain benefits.,Avoid contact with eyes, mouth, and broken skin; if contact occurs, rinse with water.,Do not use more than directed; systemic side effects are rare but include dizziness and rapid heartbeat.
Take this medication exactly as prescribed, usually 3-4 times daily. Swallow tablets whole with a glass of water.,Do not stop taking this drug suddenly, as this may cause a rapid increase in blood pressure.,This medication may cause dizziness or lightheadedness, especially when getting up from a sitting or lying position. Rise slowly.,Report any unexplained fever, joint pain, rash, or sore throat to your healthcare provider immediately—these could be signs of a lupus-like reaction.,Avoid alcohol, as it can increase side effects like dizziness or drowsiness.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose.
"Isocarboxazid, a monoamine oxidase inhibitor (MAOI), increases the risk of severe hypotension when combined with minoxidil, a direct-acting vasodilator used for hypertension. The MAOI potentiates the hypotensive effects of minoxidil by inhibiting the metabolism of norepinephrine and other vasoactive amines, leading to exaggerated vasodilation and blood pressure reduction. Clinically, this can result in symptomatic hypotension, dizziness, syncope, and potentially cardiovascular collapse."
"Morphine and minoxidil coadministration can lead to additive hypotensive effects, increasing the risk of severe orthostatic hypotension and syncope. Morphine's vasodilatory properties via histamine release and opioid-induced reduction in sympathetic tone synergize with minoxidil's direct arterial vasodilation, potentially causing a precipitous drop in blood pressure. This interaction is particularly concerning in patients with compromised cardiovascular function or volume depletion, and may necessitate dose adjustments or avoidance."
"Minoxidil, a potent arterial vasodilator used in hypertension and alopecia, can enhance the hypotensive effects of epoprostenol, a prostacyclin analog that directly dilates pulmonary and systemic arteries. The combined vasodilatory action may lead to additive reductions in systemic blood pressure, potentially causing hypotension, dizziness, or syncope, especially during intravenous epoprostenol infusion for pulmonary arterial hypertension. Clinical outcomes may include orthostatic hypotension, reflex tachycardia, and compromised organ perfusion if doses are not adjusted."
"Oxaprozin, a nonsteroidal anti-inflammatory drug (NSAID), can reduce the antihypertensive efficacy of hydralazine, a direct-acting vasodilator. NSAIDs inhibit prostaglandin synthesis, which can lead to sodium and fluid retention and increased vascular resistance, thereby counteracting the vasodilatory effects of hydralazine. This interaction may result in diminished blood pressure control and require dosage adjustments or alternative therapies."
"Hydralazine, a direct-acting vasodilator, may reduce the antihypertensive efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) like sulindac. NSAIDs inhibit cyclooxygenase-mediated prostaglandin synthesis, leading to sodium retention and increased vascular tone, which can antagonize the vasodilatory effects of hydralazine. This interaction may result in elevated blood pressure and diminished control of hypertension in patients receiving both agents."
"Hydralazine, a direct-acting vasodilator, may reduce the antihypertensive efficacy of Tolfenamic acid, a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits cyclooxygenase (COX) enzymes. The interaction arises because Tolfenamic acid's inhibition of COX-2 reduces synthesis of vasodilatory prostaglandins (e.g., prostacyclin) in the vascular endothelium, which counteracts the vasodilation induced by Hydralazine. Clinically, this can lead to blunted blood pressure reduction, potentially requiring dose adjustments or alternative therapies to maintain adequate hypertension control."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MINOXIDIL EXTRA STRENGTH (FOR MEN) vs Hydralazine, answered by our medical review team.
MINOXIDIL EXTRA STRENGTH (FOR MEN) is a Vasodilator / Hair Growth Stimulant that works by Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arterioles. It increases blood flow to hair follicles and prolongs the anagen (growth) phase of hair follicles.. Hydralazine is a Vasodilator that works by Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle, leading to decreased peripheral vascular resistance and blood pressure. Its exact mechanism is unclear but may involve interference with calcium movement and increased c GMP levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MINOXIDIL EXTRA STRENGTH (FOR MEN) and Hydralazine depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MINOXIDIL EXTRA STRENGTH (FOR MEN) is: Topical: 1 m L of 5% solution (50 mg) applied to the scalp twice daily. Maximum daily dose: 2 m L (100 mg).. The standard adult dose of Hydralazine is: 10-50 mg orally every 6 hours, titrate to maximum 300 mg/day; 10-20 mg intramuscularly or intravenously every 4-6 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MINOXIDIL EXTRA STRENGTH (FOR MEN) and Hydralazine in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MINOXIDIL EXTRA STRENGTH (FOR MEN) is classified as Category A/B. Minoxidil is pregnancy category C. First trimester: Animal studies show fetal abnormalities (skeletal, cardiovascular) at high doses; no adequate human studies. Second/third trimes. Hydralazine is classified as Category A/B. FDA Pregnancy Category C. First trimester: No well-controlled studies; animal studies show no evidence of teratogenicity but embryotoxicity at high doses. Second/Third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.